Neuphoria Therapeutics (NEUP) Cash from Financing Activities (2023 - 2025)
Neuphoria Therapeutics (NEUP) reported Cash from Financing Activities of $14.7 million for Q4 2025, up 13242.71% year-over-year from N/an in Q4 2024, and up 350.65% on a QoQ basis from $3.3 million in Q3 2025.
Neuphoria Therapeutics (NEUP) has 3 years of Cash from Financing Activities data on file, last reported at $14.7 million in Q4 2025.
- Quarterly Cash from Financing Activities rose 13242.71% year-over-year to $14.7 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $18.6 million (up 134.36% YoY) and the FY2025 annual result came in at $1.5 million, down 89.88% from the prior year.
- Cash from Financing Activities climbed to $14.7 million in Q4 2025 per NEUP's latest filing, from $3.3 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $14.7 million in Q4 2025 and bottomed at -$227338.0 in Q3 2024.
- The 3-year median for Cash from Financing Activities is $1.5 million (2024), against an average of $3.5 million.
- The widest annual swing landed in 2024, when Cash from Financing Activities slumped 137.11%; it then soared 13242.71% in 2025.
- Tracing NEUP's Cash from Financing Activities over 3 years: stood at $5.6 million in 2023, then sank by 101.98% to -$111562.0 in 2024, then soared by 13242.71% to $14.7 million in 2025.
- Per Business Quant, the three latest NEUP Cash from Financing Activities figures stand at $14.7 million (Q4 2025), $3.3 million (Q3 2025), and $704675.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14.66 Mn |
| Dec 31, 2025 | 14.66 Mn |
| Sep 30, 2025 | 3.25 Mn |
| Sep 30, 2025 | 3.25 Mn |
| Jun 30, 2025 | 704,675.00 |
| Jun 30, 2025 | 704,675.00 |
| Mar 31, 2025 | 1.16 Mn |
| Mar 31, 2025 | 1.16 Mn |
| Dec 31, 2024 | -111,562.00 |
| Dec 31, 2024 | -111,562.00 |
| Sep 30, 2024 | -227,338.00 |
| Sep 30, 2024 | -227,338.00 |
| Jun 30, 2024 | 7.12 Mn |
| Jun 30, 2024 | 7.12 Mn |
| Mar 31, 2024 | 1.75 Mn |
| Mar 31, 2024 | 1.75 Mn |
| Dec 31, 2023 | 5.63 Mn |
| Dec 31, 2023 | 5.63 Mn |
| Sep 30, 2023 | 612,538.00 |
| Sep 30, 2023 | 612,538.00 |